Farmak Pharmaceuticals UK Ltd, a subsidiary of Farmak International from the Ukrainian pharmaceutical group “Farmak”, on September 19 completed the acquisition of the British group of pharmaceutical companies specializing in generics, A&S Pharma Holdings.
“The group holds WDA, MIA and MS licenses and specializes in sourcing and licensing off-proprietary pharmaceuticals (generics) for the UK market, with dozens of marketing authorizations and additional applications under development,” – it is said in the message of Farmak International.
It is notedthat Farmak Pharmaceuticals UK will retain the group’s founder and team following the acquisition, seeking to strengthen its business development capabilities in the UK through an established network of international partners.
Investment banking company FinPoint acted as Farmak International’s exclusive financial advisor in this acquisition.
The price of the deal is not disclosed.
“We are pleased to welcome A&S Group into the Farmak International family. This acquisition is fully in line with our strategy to expand our presence in key markets,” said Farmak International CEO Viktor Kostyuk in the release.
According to Farmak International Chief Commercial Officer (CCO) Mark Westermann, the group’s market knowledge and established partnerships will strengthen Farmak’s commercial capabilities in the UK and international markets by offering a wider range of generics.
According to Mark Hourigan, CEO of Farmak Pharmaceuticals UK, the purchase of A&S Group, taking into account its extensive network and the group’s commercial experience, will allow us to accelerate expansion into new therapeutic areas and new markets in the UK and in subsidiaries in international markets.
The move is said to be part of Farmak International’s broader global growth strategy and follows the recent acquisition of Polish company Symphar in March 2024, 2023 acquisitions in the Czech Republic and Slovakia, and a brownfield investment in Spain in 2022.
“This acquisition demonstrates our desire for global leadership in pharmaceuticals,” Kostiuk said.
According to the release, the pharmaceutical company Farmak, founded in 1925, is engaged in research, development, production and global distribution of generics. The group has at its disposal production and research facilities in Ukraine and Spain, and also has 12 commercial representative offices in the world, in particular in Switzerland, Great Britain, Spain, Poland, Slovakia, Czech Republic, UAE, Ukraine, Vietnam, Uzbekistan, Kazakhstan and Kyrgyzstan. Farmak International exports products to 60 countries, including 15 EU member states, as well as to the markets of Central and South America, the Middle East, Asia, Africa and Australia.
Farmak Pharmaceuticals UK is a key regional hub for expanding the market presence and supply of pharmaceutical products in Great Britain and Ireland.
According to data in the British register, Farmak Pharmaceuticals UK, registered in April 2022, is owned by Farmak AG – 65%, Hourigan – 25% and Kostyuk – 10%.
Also established in April 2022, A&S Pharma Holdings Ltd in March of this year registered a pledge to secure obligations to the British Crescent Pharma Limited, a fast-growing independent generics company established in 2003, and on September 19, A&S Pharma Holdings announced the fulfillment of these obligations Yazan
